EU finishes talks on COVID-19 vaccine deal with French biotech company, Valneva

The European Commission has finished exploratory talks with the French biotechnology company, Valneva, on a COVID-19 vaccine deal that would enable EU countries to purchase 30 million doses, with 30 million more optioned.  

The Commission has already struck vaccine deals on behalf of EU member states with six other companies: AstraZenecaSanofi-GSKJanssen Pharmaceutica NV (Johnson & Johnson), BioNTech-Pfizer, CureVac, and Moderna, in addition to having recently concluded talks with Novavax.

As with the other deals, member states will be able to donate Valneva vaccines to lower- and middle-income countries or re-direct them to other European countries.

Press release - European Commission